The only zero-prep, full-montage, rapid EEG solution for clinical use now offers near real-time notification of ongoing seizures by using reliable FDA cleared seizure detection software

SANTA CLARA, Calif. - December 1, 2022 - (Newswire.com)

Zeto, Inc., an innovative EEG brain monitoring company, announced today the integration of FDA cleared seizure detection and trending algorithms developed by encevis, now available as part of the Zeto EEG platform. encevis is powered by the AIT Austrian Institute of Technology, a renowned research and technology organization in Europe, and their EEG analysis software is widely utilized and peer reviewed by physicians across the world.

These new tools will help Zeto's customers speed up EEG reviews. The trending module graphically reports several hours of EEG into a simple display to allow rapid assessment of brain states. The seizure detection component offers high sensitivity with low false alarm rates, matching and in parts surpassing industry benchmarks. Proven by three independent clinical publications, and harvesting the power of AI and deep learning, the software provides a detailed overview of seizures and suspicious EEG activity.

"According to current studies, 18% of critically ill patients with serious brain diseases suffer from unrecognized non-convulsive epileptic seizures, frequently leading to neurological disabilities. The joint efforts of Zeto and encevis will make EEG faster to read by automatically detecting and orienting the reader to abnormalities. Seizures will be automatically detected and marked in the EEG for review. Near real-time detection notifies medical staff about patients with ongoing clinical seizures," said Dr. Tilmann Kluge, head of Medical Signal Analysis of AIT.

"We are excited to integrate encevis' seizure detection and trending tools into our platform. Collaborative projects such as this ensure a seamless user experience and enable healthcare providers to offer the best care to their patients at an affordable price," said Florian Strelzyk, Chief Sales Officer at Zeto.

Zeto EEG analysis features will continue to evolve as more third party integrations become available. Zeto is committed to driving innovation in brain monitoring by opening its platform to strategic projects and partnerships that empower health care providers to diagnose their patients rapidly and more effectively.

About Zeto

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, California, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto's revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. 

To learn more about Zeto's products, including the remote EEG monitoring, please visit: https://zeto-inc.com or email us at [email protected].

About encevis

encevis is a part of the AIT Austrian Institute of Technology, Austria's largest non-university research institute, is among the European research institutes a specialist in the key infrastructure issues of the future.

Learn more: https://www.encevis.com

Contact Information:
Irina Nazarova
Marketing Manager
[email protected]
9174351226


Press Release Service by Newswire.com

Original Source: Zeto Implements encevis' Seizure Detection and Trending Algorithms

NEW YORK - December 1, 2022 - (Newswire.com)

Obesity has become a rising public health concern with its association with diseases, including type 2 diabetes, cardiovascular disease, non-communicable respiratory diseases, and cancers. As per the data predicted by the World Obesity Atlas 2022, one billion people globally, including 1 out of 5 women and 1 out of 7 men, will be living with obesity by 2030. With high rates of obesity, it is important to find a solution. That's where weight loss clinics like NextMed enter.

Significance of Medical Weight Loss Clinics

NextMed provides comprehensive weight loss services. This includes medical evaluations, nutritional counseling, lifestyle advice, and physical activity programs. The popular weight loss clinic offers prescription medications or other treatments to help people achieve their goals. In addition to helping individuals lose weight, they provide constant support & assistance to maintain a healthy lifestyle.

There are many different reasons why people choose to visit a weight loss clinic. For some, it may be a last resort after trying other weight loss methods without success. Others may feel more comfortable in a group setting or appreciate the support and motivation these clinics can provide.

Weight loss clinics are an essential resource for those struggling with obesity. They can help people lose weight in a safe and controlled environment and provide the support and motivation needed to maintain long-term weight loss.

Weight-loss Journey at NextMed

NextMed is committed to helping people achieve health goals, and their science-backed FDA-approved medication and weight loss plans have helped thousands of members lose over 53 lbs on average. With NextMed, losing weight doesn't have to be complicated - it's easy to start, and their support team is always here to help. Don't wait - call today.

GLP-1a drugs, such as Doctor Prescribed Ozempic, Mounjaro, Saxenda, Rybelsus, Trulicy, Victoza, and Wegovy, are a type of medication that can help promote weight loss by increasing satiety and reducing appetite. Generic Contrave (Bupropion/Naltrexone) is another effective weight-loss drug. Metformin is also sometimes used for this purpose. All these medications used by NextMed are FDA-approved, with demonstrable weight loss in years-long clinical studies.

All these drugs can be effective when used properly, but it is essential to remember that they are not magic bullets. Weight loss still requires effort and lifestyle changes on the part of the individual. These drugs can help customers by giving the extra boost needed to achieve weight-loss goals.

Most customers lose an average of 23% of body weight. The average member has a starting weight of 230 pounds and can lose 53 pounds (23% weight loss). NextMed offers genuine doctors and a provider-led weight loss program. Additionally, monthly medical check-ups help track progress toward a goal while providing feedback about how things may be going otherwise.

NextMed's generic weight loss plan provides customers flexibility and control over goals. Looking for Wegovy Medication Online, contact us today and learn more on Weight Loss Medication Online!

Contact Information:
Frank Leonardo
Sr. Manager
[email protected]
914 426 1993


Press Release Service by Newswire.com

Original Source: Rising Obesity Rates; NextMed to the Rescue

Virgo is first investment for new GI fund.

CARLSBAD, Calif. - December 1, 2022 - (Newswire.com)

Virgo Surgical Video Solutions ("Virgo") today announced that the company received an investment from the American Gastroenterological Association ("AGA"), AGA's new venture capital fund, GI Opportunity Fund 1.  

"While AGA has long guided innovators who share our goal of improving digestive healthcare, we have doubled down on this commitment by establishing the GI Innovation Fund. The fund's first investment - Virgo - exemplifies our pursuit of improved clinical care," says Lawrence Kosinski, MD, AGAF, AGA Governing Board Councilor for Development and Growth. "Through our venture fund, gastroenterologists can join AGA to invest in fast-growing, early-stage companies that are transforming care for patients with digestive disease." 

Virgo provides gastroenterologists, clinical trial sponsors, and trial site investigators with AI-fueled, always-on endoscopic procedure recording and patient recruitment tools for clinical trials in gastroenterology, starting with inflammatory bowel disease clinical trials. 

"Virgo would not be where it is today without the support of the AGA, dating back to our initial pitch at the AGA Tech Summit's Shark Tank competition in 2018," said Matt Schwartz, Virgo co-founder and Chief Executive Officer. "Virgo is proud to have the support of the AGA, and this investment will help accelerate Virgo's mission to improve patient outcomes and clinical workflows by developing automation and AI tools for endoscopy." 

"As its partner in the GI Opportunity Fund, Varia shares the AGA's passion of supporting exciting innovations that benefit the GI field. Our partnership is designed, however, to do more than that. We firmly believe that this fund can also create an unusual opportunity for members interested in venture capital investing at an unusually low entry point. We believe we can accomplish these multiple objectives by making investments in companies like Virgo Surgical Video Solutions. Its video capture, management, and artificial intelligence analysis technology platform holds great promise for advancing the field of endoscopic medicine," said Scott Friedman, Varia Ventures co-founder and managing partner. 

More information about the AGA's GI Opportunity Fund 1 is available at https://againvest.varia.com/.  

About Virgo  

Virgo provides the leading cloud video capture, management, and artificial intelligence analysis platform for endoscopic medicine. Academic, integrated, and private practice healthcare providers use the Virgo platform to advance patient care through video-based research and training initiatives. Since launching, Virgo has helped physicians capture over 400,000 endoscopy procedures using industry-leading HIPAA, HITRUST, and SOC 2-compliant cloud service providers. Virgo also supports integration with all leading electronic health records systems. In 2021, Virgo launched a suite of tools called VirgoTrials, which help pharmaceutical trial sponsors and their participating trial sites accelerate patient recruitment and shorten the overall enrollment period for trials. For more information, visit www.virgosvs.com. 

About AGA  

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. For more information, visit www.gastro.org.  

The AGA Center for GI Innovation and Technology supports innovation and the development of new technology in gastroenterology, hepatology, nutrition and obesity by guiding medical device and therapeutics innovators through the technology development and adoption process. 

About Varia Ventures  

Varia Ventures is a next-generation venture capital platform for professional organizations interested in building wealth for themselves and their members through investing in a portfolio of highly curated, emerging companies originating from their organizations. Varia's platform blends insights from key opinion leaders, strategic partners, and industry experts through its "end-to-end" technology solution designed to both support early-stage companies while providing compelling investment opportunities to its investors. For more information, visit variaventures.com. 

Contact Information:
Jake Hungarter
Marketing
[email protected]
+14848960602


Press Release Service by Newswire.com

Original Source: AI-Fueled Endoscopy Capture and Clinical Trials Platform, Virgo Surgical Video Solutions, Receives Support From American Gastroenterological Association Venture Fund

New suite of time-saving products address pathology, cytology and histology laboratory staffing shortages and storage inefficiencies.

STERLING HEIGHTS, Mich. - December 1, 2022 - (Newswire.com)

SPOT Imaging proudly announces a new generation of sample-tracking and administration tools designed specifically to address today's staffing shortages and storage accuracy concerns. BlocDoc™, PathTracker™ and PathArchiv™ operate as an integrated system - or separately within existing lab systems - to significantly transform the efficiency and precision of the sample-tracking process.

Created in association with leading pathologists, SPOT Imaging's new product suite delivers cost savings and superior accuracy. Pathology, cytology and histology laboratories no longer need extensive teams of experienced laboratory technicians for sample handling.

BlocDoc™ turns physical paraffin blocks into digital assets for quick electronic sharing and tracking instead of a technician physically addressing and shipping samples. The digital assets make questions of tissue completeness trivial and routine rather than a labor-intensive, exceptional request, meeting the intent of the CAP Accreditation Committee when they added this requirement to the laboratory accreditation checklist. 

PathTracker™ bulk scans cassette and slide transport containers, across the histology process, ensuring the timely recovery of lost or late samples. Time-consuming and error-prone hand scanning is replaced with a simple image and electronic scan of the full container that is 8-18 times faster than hand scanning. Captured barcodes are automatically uploaded to an LIS.

PathArchiv™, a file room sample management system, virtually eliminates lost samples and saves 4-8 times the full-time equivalent technician resource, providing 30% greater storage density while fitting directly on most existing shelving units. When samples are loaned, PathArchiv™ automatically tracks the destination and return due date. Its non-sequential workflow filing methodology eliminates refiling costs.

"SPOT Imaging provides state-of-the-art technology to solve the most pressing problems administrators and pathologists face today: too few technicians to handle an overabundance of samples and data," states Philip Merlo, Vice President, SPOT Imaging. "Each of our new products will work with existing laboratory computing and storage infrastructure. Our collaboration with pathologists delivers products that meet real-world challenges in cost-effective and time-efficient ways."

On-site demonstrations of BlocDoc™, PathTracker™ and PathArchiv™ are available to laboratories endeavoring to achieve substantial cost-savings and greater tracking accuracy.  

About SPOT Imaging

SPOT Imaging provides end-to-end imaging solutions specifically designed for histology, cytology and pathology laboratories. The company's technologies substantially improve workflow efficiencies while increasing sample accuracy through the automated digitization of sample assets that provides the foundation for virtual sharing and tracking across the laboratory workflow and network user base.

Featuring proprietary designs and in-house manufacturing, SPOT Imaging is recognized worldwide for the ease of use, excellent performance and high reliability of its imaging products and end-to-end solutions. SPOT Imaging digital cameras and extended systems are integral to the operations of some of the most prestigious medical institutions, including Duke University, the University of Michigan, Stanford University, the Cleveland Clinic and the Mayo Clinic. For more information, visit www.spotimaging.com.

Contact Information:
Joni Jones
Marketing Manager
[email protected]
248-854-4378


Press Release Service by Newswire.com

Original Source: SPOT Imaging Announces Cost-Saving Sample Tracking, Storage and Management Solutions

Goynes-Brown Breaks Glass Ceiling as First Black Mayor in the State

LAS VEGAS - December 1, 2022 - (Newswire.com)

The City of North Las Vegas' new Mayor, Pamela Goynes-Brown, officially takes office today, becoming the first black Mayor in Nevada history. Goynes-Brown, a longtime educator turned public servant, previously served as Councilwoman of North Las Vegas' Ward 2 and was the first female African American Councilwoman in her previous role. She also was the first female African American Mayor Pro-Tempore, having served in that role twice. Goynes-Brown's recent election as Mayor continues her streak of breaking barriers. 

After referencing records via the University of Nevada Las Vegas (UNLV) School of Public Policy, the UNLV Oral History Research Center and relevant municipal leadership organizations, Goynes-Brown's victory sets a new precedent in Nevada's 158-year history and the approximately 400 mayoral elections of the State's 19 incorporated cities over that time.

Goynes-Brown leads the charge for the City of North Las Vegas, the third-largest municipality in Nevada and one of the largest minority-majority cities in America.

"Why has it taken so long?" Mayor Goynes-Brown asked. "I don't know, but I know it is happening right now and that is what's important — I'm so proud that the City of North Las Vegas has once again been the leader in making huge positive strides for our state and residents.

"It is an incredible honor to serve the constituents of the City of North Las Vegas, one of the most diverse cities in America," Goynes-Brown continued. "To set the stage for young boys and girls in North Las Vegas, to see themselves represented from the Mayor's seat to our Executive offices to the Team Members who serve our community each day, I believe the City of North Las Vegas embodies the beautifully diverse future of this country and I am honored to serve as Mayor." 

The City of North Las Vegas was the first municipality in the state to formally recognize June 19 as the Juneteenth holiday when the City Council passed Resolution 2665 in June 2021. That October, the North Las Vegas City Council approved updated contracts with employee bargaining units to add Juneteenth as an official City holiday and close City facilities in recognition. The City of North Las Vegas currently has a bill at the State Legislature proposing to make Juneteenth a State Holiday, as well as a bill proposing to allow people who are legally authorized to work in the United States to become peace officers, removing the requirement that they be a U.S. citizen.

"We must continue to call out institutional racism. We must continue to work to bring equity to all aspects of government. I look forward to working to continue to make strides for our community and for the people of color who call it home," said Mayor Goynes-Brown. "As I take office, the City of North Las Vegas will continue to advocate and prioritize our diverse residents and their needs."

For more information on all of these efforts and more, visit www.cityofnorthlasvegas.com.

About The City of North Las Vegas

North Las Vegas stretches across the northern rim of the Las Vegas Valley and is home to more than 275,000 residents. As a premier place to live, work and play, North Las Vegas leads the valley in new home development while maintaining a longstanding tradition of successful economic development in a business-friendly environment. The City of North Las Vegas' fast and faster approach has made the city a top destination in the country for development opportunities. North Las Vegas is a hub for new job creation and economic diversification that attracts global brands, innovative industries, manufacturing, e-commerce, and logistics centers.

Contact Information:
Cheryl Bella
PIO
[email protected]
702-499-3930

Brittany Toth
Director of Communications
[email protected]
702-218-0232


Press Release Service by Newswire.com

Original Source: City of North Las Vegas Mayor Makes Nevada History

Agfa HealthCare announced Mark Burgess as President North America Agfa HealthCare, effective October 2022. New appointment joins recently reinvigorated roster of leadership at both global and regional levels.

GREENVILLE, S.C. - November 30, 2022 - (Newswire.com)

Agfa HealthCare announced Mark Burgess as President North America Agfa HealthCare, effective October 2022. Burgess is based in Raleigh, North Carolina.

"Mark Burgess comes to Agfa HealthCare to lead our focus on building and delivering long-term strategic benefits to the North American healthcare provider clients we serve.  He understands the value of working side-by-side with health systems to help them meet their goal to deliver quality patient care," said Nathalie McCaughley, President, Agfa HealthCare. "He and his teams in the U.S. and Canada will expand the company's reach in providing guidance to new and existing clients in implementing and adopting the Agfa HealthCare Enterprise Imaging Platform, to allocate resources effectively, control the total cost of care, and enhance patient-and-provider relationships and satisfaction."

With extensive experience in healthcare information technology, Burgess joined Agfa HealthCare from NextGen HealthCare, where he was Senior Vice President, Ambulatory Markets. He has also held leadership positions at Cerner (now Oracle Cerner) and Allscripts and, throughout his career, managed sales, consulting, product management and corporate strategy. 

"I am very excited to be joining the Agfa HealthCare team as we approach the tipping point of Enterprise Imaging adoption," said Mark Burgess. "I believe that Agfa's unique vision of guiding health systems to improve accessibility and integration of medical imaging will improve their efficiency, collaboration and clinical outcomes across disciplines and geographies. Our platform technology keeps clinicians focused on what matters most: diagnosis and treatment of patients."

About Agfa HealthCare
Agfa HealthCare is transforming the role of medical imaging into a high-impact, data-driven enterprise-wide information flow - supporting health professionals across the globe with secure and scalable imaging data management. The company's mission is to provide the solutions and guiding experience to help clients improve productivity, manage resource allocation, and mitigate complexity and redundant technologies while providing clinical confidence with readily available patient-centric information. 

The company's preeminent product, the Enterprise Imaging Platform, creates an Imaging Health Record™ or IHR, to align with and fulfill a health system's EHR/digital transformation strategy. The IHR provides an unobstructed flow of patient imaging information to help care providers achieve their clinical, operational, and business strategies.

Agfa HealthCare is a division of the Agfa-Gevaert Group which is headquartered in Mortsel, Belgium, and traded on Euronext Brussels (AGFB).

Contact Information:
Miriam Ladin
Marketing and Communication Americas
[email protected]
+1 978 284 7777


Press Release Service by Newswire.com

Original Source: Mark Burgess Named President North America, Agfa HealthCare

BUFFALO, N.Y. - November 30, 2022 - (Newswire.com)

POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2 clinical trial of EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes. Data from this clinical study has been published today in BMC Medicine (https://doi.org/10.1186/s12916-022-02661-1).

EuCorVac-19 is an RBD-based vaccine consisting of POP BIO's Spontaneous Nanoliposome Antigen Particle (SNAP) technology in combination with the adjuvant genetically modified E. coli Monophosphoryl Lipid A (EcML), produced by EuCorVac-19 manufacturer Eubiologics (KOSDAQ: 206650). Use of SNAP technology enables co-delivery, as opposed to co-administration, of antigen with adjuvant, packed in an immunogenic nanoparticle format free of any carrier protein. 

In this Phase II clinical study, 229 participants were enrolled at five clinical sites in South Korea. Healthy adults aged 19-75 without prior exposure to COVID-19 were dosed on day 0 and day 21 between July and October 2021. The most common local adverse events were low-grade injection site tenderness and pain, while the most common systemic adverse events were low-grade fatigue, myalgia, and headache. No clinical abnormalities were detected, and no serious adverse effects were solicited by EuCorVac-19. Adverse events did not increase with the second dosing. On day 42, Spike IgG geometric mean ELISA titers were 0.8, 211, and 590 Spike binding antibody units (BAU/mL) for placebo, low-dose, and high-dose EuCorVac-19, respectively (p < 0.001 between groups). No anti-his-tag antibodies were detected. Neutralizing antibody levels of the low-dose and high-dose EuCorVac-19 groups had FRNT50 geometric mean values of 129 and 316, respectively. Boosting responses and dose responses were observed. Antibodies against the RBD correlated with antibodies against the Spike and with virus neutralization.

The published data shows that in this trial, EuCorVac-19 was well-tolerated and induced antibodies in a dose-dependent manner that neutralizes SARS-CoV-2. The unique liposome display approach of EuCorVac-19, which lacks any immunogenic protein components besides the antigen itself, coupled with the lack of increased adverse events during boosting suggests the vaccine platform is amenable to multiple boosting regimes in the future to help control the ongoing COVID-19 pandemic. 

"The results of this Phase II trial provide critical evidence of the value of the SNAP platform. This data provides invaluable support towards our platform's development, further enabling the creation of new vaccines with the potential to alleviate suffering worldwide," says POP BIO co-founder Jonathan Smyth.

"The unique qualities of the SNAP adjuvant system enabled simple conversion of protein antigens into immunogenic particles that safely induced virus-neutralizing antibodies. We look forward to further study of this technology for the prevention of COVID-19 and other diseases," says company co-founder and study co-author Jonathan Lovell. 

Presently, EuCorVac-19 is undergoing two Phase III clinical studies in simultaneous studies in the Philippines and the Democratic Republic of Congo. EuBiologics is working with international research organizations to expedite recruitment and analyze trial results to accelerate regulatory approval of EuCorVac-19.

POP BIO is developing new vaccine product candidates and is seeking further collaborators around the SNAP technology to make use of the unique qualities of the vaccine platform technology.

POP Biotechnologies (POP BIO): POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from The State University of New York Research Foundation (SUNY-RF), was developed by company founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo).

POP BIO's SNAP Technology: POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and other diseases through the use of cobalt-modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in antigen-specific immune responses.

About EuBiologics: EuBiologics is a South Korean biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens and EcML. The total capacity of COVID-19 vaccine is in the hundreds of millions of doses per year.

About EuBiologics' EuIMT Technology: EuBiologics' Immune Modulation Technology uses genetically engineered Monophosphoryl Lipid A (MLA), termed EcML, a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems. Eubiologics' EcML and POP BIO's SNAP technologies synergize to create potent next-generation vaccines.

Contact Information:
Jonathan Smyth
President
[email protected]
+13152200087


Press Release Service by Newswire.com

Original Source: POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

VNA launched Moving Healthcare Forward Podcast

RED BANK, N.J. - November 30, 2022 - (Newswire.com)

VNA Health Group launched a new healthcare-focused podcast, The Moving Healthcare Forward Podcast, on iTunes and Spotify, as part of their massive strategic initiative and four-year plan to move healthcare forward by making care more equitable, creating the workforce of tomorrow, impacting behavioral health and bringing dignity to aging.

VNAHG President and CEO Dr. Steven Landers hosts The Moving Healthcare Forward Podcast, where he has conversations with leaders in the healthcare space. Together, Landers and his guests will discuss how to address the massive challenges facing the healthcare industry, including how to provide the best care for everyday people, especially the most vulnerable.

"I'm thrilled to launch this podcast," Landers said, "because I know that it will help VNAHG push forward the bold opportunities we have to do good in healthcare, particularly home healthcare. It's also a project close to my heart: As a certified family doctor and geriatrician, The Moving Healthcare Forward Podcast allows me to fuse together my experience in geriatric medicine, home health and palliative care with what I see as my purpose, bridging the gaps in healthcare inequity."

The first episode features an interview with Bill Dombi, President of the National Association for Home Care & Hospice, and is available on iTunes and Spotify. Dombi and Landers discuss the importance of at-home and hospice care and the reimbursement cuts they are facing, Medicare Advantage's lasting impact and incredible recent advancements in care.

"[Some of our advances] may seem like they're incremental," Dombi said on the podcast, "but the way my measuring stick goes, for every time you get kicked back a step, healthcare at home has taken us two steps forward. We're making that progress. When we talk to healthcare providers who work in-home, they basically say the same thing, 'I would not want to work anywhere else.'"

###

ABOUT VNAHG: VNAHG is the nation's second-largest not-for-profit home healthcare organization servicing New Jersey and Ohio. For more than 100 years, they've provided customized care to individuals with chronic diseases and conditions, as well as those who need short-term care. From post-operative nursing and rehabilitation services and speech therapy to wound care and live-in private care — and just about everything in between — their skilled multidisciplinary team delivers the highest level of care possible.

ABOUT DR. STEVEN LANDERS: Dr. Landers is the President and CEO of  VNAHG, along with the host of The Moving Healthcare Forward Podcast. As a certified family doctor and geriatrician, he has a specialized interest in geriatric medicine, home health, hospice and palliative care. Dr. Landers is a graduate of the Case Western Reserve University School of Medicine and the Johns Hopkins University School of Hygiene and Public Health. He has authored several articles on the role of home care in national publications, including the New England Journal of Medicine and the Journal of the American Medical Association.

Contact Information:
Kristi Bridges
CEO & President of The Sawtooth Group
[email protected]
732.492.4520

Elisa Altini
Account Executive at The Sawtooth Group
[email protected]
718.510.6425


Press Release Service by Newswire.com

Original Source: VNAHG President and CEO Launches Healthcare-Focused Podcast